Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Birzeit Pharmaceutical CoXPAE:BPC +0.28%87 EV-to-EBITDA is 9.04 as of Aug. 12, 2026, which is 5% below its 10-year median of 9.54. GuruFocus rates XPAE:BPC with a GF Score™ of 87/100 and a GF Value™ of $4.59 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 734 Drug Manufacturers companies, Birzeit Pharmaceutical Co ranks better than 66.89% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Birzeit Pharmaceutical Co's enterprise value is $138.34 Mil.
Birzeit Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $15.30 Mil. Therefore, Birzeit Pharmaceutical Co's EV-to-EBITDA for today is 9.04.
The historical rank and industry rank for Birzeit Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
XPAE:BPC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.47 Med: 9.54 Max: 34.47
Current: 9.05
During the past 13 years, the highest EV-to-EBITDA of Birzeit Pharmaceutical Co was 34.47. The lowest was 6.47. And the median was 9.54.
XPAE:BPC's EV-to-EBITDA is ranked better than 66.89% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.33
vs XPAE:BPC: 9.05
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Birzeit Pharmaceutical Co (XPAE:BPC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Birzeit Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Birzeit Pharmaceutical Co's share price for today is $3.64.
Birzeit Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.324.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAE:BPC vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Birzeit Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Birzeit Pharmaceutical Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Birzeit Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Birzeit Pharmaceutical Co's EV-to-EBITDA falls into.
Birzeit Pharmaceutical Co's current Enterprise Value is $138.34 Mil.
Birzeit Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Birzeit Pharmaceutical Co (XPAE:BPC) has a EV-to-EBITDA of 9.04 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Birzeit Pharmaceutical Co. This is near median its historical median of 9.54. Over the past decade, Birzeit Pharmaceutical Co's EV-to-EBITDA has ranged from 6.47 to 34.47. According to the industry distribution chart, Birzeit Pharmaceutical Co ranks #243 out of 734 companies in the Drug Manufacturers industry, placing it in the top 33.1%.
Is Birzeit Pharmaceutical Co's EV-to-EBITDA too high?
Birzeit Pharmaceutical Co's current EV-to-EBITDA of 9.04 is near median its 10-year median of 9.54. Over the past 10 years, this metric has ranged from a low of 6.47 to a high of 34.47. The Drug Manufacturers industry median EV-to-EBITDA is 13.33. Birzeit Pharmaceutical Co's value of 9.04 is 32.2% below this industry median. Based on the distribution chart, Birzeit Pharmaceutical Co ranks #243 out of 734 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Birzeit Pharmaceutical Co has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Birzeit Pharmaceutical Co's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Birzeit Pharmaceutical Co ranks #243 out of 734 companies for EV-to-EBITDA. This puts Birzeit Pharmaceutical Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.33. Birzeit Pharmaceutical Co's value of 9.04 is 32.2% below this benchmark. Historically, Birzeit Pharmaceutical Co's own EV-to-EBITDA has ranged from 6.47 to 34.47 over the past decade. While the company's 10-year median is 9.54 vs. the industry median of 13.33, Birzeit Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.33, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Birzeit Pharmaceutical Co's current EV-to-EBITDA of 9.04 is 32.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Birzeit Pharmaceutical Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Birzeit Pharmaceutical Co's current EV-to-EBITDA is 9.04, which is near median its own 10-year median of 9.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Birzeit Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co (XPAE:BPC) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.59, compared to a current price of $3.64 — trading 20.7% below its estimated fair value. The current EV-to-EBITDA is 9.04, which is near median its 10-year median of 9.54 and 32.2% below the Drug Manufacturers industry median of 13.33. Birzeit Pharmaceutical Co's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Birzeit Pharmaceutical Co (XPAE:BPC), the current EV-to-EBITDA is 9.04 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Birzeit Pharmaceutical Co (XPAE:BPC) Overvalued in 2026?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co stock appears to be undervalued.
The current stock price of $3.64 is trading 20.7% below its estimated GF Value™ of $4.59.
GuruFocus considers Birzeit Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for XPAE:BPC:
EV-to-EBITDA: 9.04 (near median its 10-year median of 9.54)
GF Value™: $4.59 vs. price of $3.64 (20.7% below fair value)
Industry Position: 32.2% below the Drug Manufacturers median (#243 of 734)
No single metric tells the full story. See the XPAE:BPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Birzeit Pharmaceutical Co operates as a pharmaceutical manufacturer in Palestine, producing a range of approximately 270 products across various production lines at four locations. Its portfolio comprises brands spanning multiple therapeutic areas. In addition to manufacturing, the company supplies its products to the local market through pharmacies and medical professionals.
87GF Score
Get the complete analysis for XPAE:BPC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:BPC has been successfully added to your 
